Last updated: August 14, 2026

Application No. 18/648,410

SULFONYL FUNCTIONAL COMPOUND, METHODS AND USES THEREOF

Non-Final OA

Filed

Apr 28, 2024

Priority

Sep 07, 2023 — CN 202311151393.1

Examiner

BELL, SARA ELIZABETH

Art Unit

Tech Center

Assignee

Wuhan Pinestone Technology Co. Ltd.

OA Round

1 (Non-Final)

Interview Optional

— +38.2% interview lift. Examiner has a relatively high allowance rate (69%); +38.2% interview lift. A written response may suffice.

Based on 55 resolved cases, 2023–2026

Examiner Intelligence

BELL, SARA ELIZABETH View full profile →

Grants 69% — above average

Career Allowance Rate

38 granted / 55 resolved

+9.1% vs TC avg

Strong +38% interview lift

Without

With

+38.2%

Interview Lift

resolved cases with interview

Typical timeline

3y 8m

Avg Prosecution

43 currently pending

Career history

105

Total Applications

across all art units

Statute-Specific Performance

§101

4.0%

-36.0% vs TC avg

§103

22.4%

-17.6% vs TC avg

§102

26.2%

-13.8% vs TC avg

§112

30.4%

-9.6% vs TC avg

Black line = Tech Center average estimate • Based on career data from 55 resolved cases

Prosecution Timeline

Apr 28, 2024

Application Filed

Aug 06, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/613,681

Patent 12702660

A METHOD FOR TREATING CANCER WITH AN ORAL DOSAGE FORM OF AN ESTROGEN RECEPTOR-ALPHA INHIBITOR

4y 8m to grant Granted Aug 11, 2026

18/018,658

Patent 12697335

METHOD FOR TREATING IMMUNE TOXICITIES INDUCED BY IMMUNE CHECKPOINT INHIBITORS

3y 6m to grant Granted Aug 04, 2026

17/826,102

Patent 12692269

THERAPEUTIC COMPOUNDS

4y 2m to grant Granted Jul 28, 2026

17/642,442

Patent 12653830

SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF

4y 3m to grant Granted Jun 16, 2026

17/801,289

Patent 12653814

BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT

3y 9m to grant Granted Jun 16, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

69%

Grant Probability

99%

With Interview (+38.2%)

3y 8m (~1y 4m remaining)

Median Time to Grant

Low

PTA Risk

Based on 55 resolved cases by this examiner. Grant probability derived from career allowance rate.